Breast Implant Associated Anaplastic Large Cell Lymphoma

Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare malignant complication of breast implants most commonly associated with Allergan BIOCELL textured –surface implants. It is estimated that the risk is 1 in 3,300. These particular breast implants have been now been withdrawn from use in Europe and are subject to a global recall.

As of 9 October 2019, the HSE has sent letters to the affected individuals to advise them of this increased risk.

There is no recommendation nationally or internationally to have these implants removed.

Individuals with breast implants are advised to be aware of any new breast symptom such as swelling, lumps, pain or asymmetry and are advised to seek medical attention from their implanting surgeon, GP, plastic surgeon or breast surgeon.

A dedicated telephone helpline number will be provided in each of the letters sent to affected individuals to receive queries, provide reassurance to individuals concerned and where appropriate organise a clinical review.

Individuals who have received implants in private hospitals will be contacted by their implant surgeon and followed up with them as appropriate.

Concerned individuals who have had their implants overseas or by another provider should make every effort to find out from the implanting hospital or provider which type of implant they have received. They should contact their GP for advice and direction in this regard.

Anyone concerned about their risk or any symptoms can contact Cancer Nurseline on 1800 200 700 or by email for advice support and information.

Date Last Reviewed: 
Wednesday, October 9, 2019